Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMPR1B | O00238 | 1/20 | 0.32 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.32 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.32 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7704567 | 0.75 | PRKCI (0.34) | BMPR1BBMPR1AACVR1BTGFBR1ACVRL1 | |
| SCHEMBL13399609 | 0.72 | ACVRL1 (0.33) | BMPR1BBMPR1AACVR1BTGFBR1ACVRL1 | |
| SCHEMBL21598429 | 0.71 | ACVRL1 (0.32) | BMPR1BBMPR1AACVR1BTGFBR1ACVRL1 | |
| SCHEMBL13382187 | 0.71 | ACVRL1 (0.32) | ACVRL1 | |
| SCHEMBL22516999 | 0.71 | CCR1 (0.41) | BMPR1BBMPR1AACVR1BTGFBR1ACVRL1 | |
| SCHEMBL29952495 | 0.71 | CCR1 (0.41) | BMPR1BBMPR1AACVR1BTGFBR1ACVRL1 | |
| SCHEMBL30147923 | 0.71 | ACVRL1 (0.32) | BMPR1BBMPR1AACVR1BTGFBR1ACVRL1 | |
| SCHEMBL1145581 | 0.61 | ABCG2 (0.50) | — | |
| SCHEMBL29664379 | 0.61 | — | — | |
| SCHEMBL21893885 | 0.59 | BUB1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462623-B2 | Quinazoline derivatives as Src tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2008-12-09 | — | — | US | disclosed |
| EP-1562955-B1 | QUINAZOLINE DERIVATIVES AS SRC TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| US-20060122199-A1 | Quinazoline derivatives as src tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2006-06-08 | — | — | US | disclosed |
| EP-1562955-A1 | QUINAZOLINE DERIVATIVES AS SRC TYROSINE KINASE INHIBITORS | Astrazeneca AB (SE) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004041829-A1 | QUINAZOLINE DERIVATIVES AS SRC TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122199-A1 | Quinazoline derivatives as src tyrosine kinase inhibitors | SRC, ABL1, ERBB2 | BMPR1B 4228/4885BMPR1A 4439/4885ACVR1B 3177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.